We recently updated our Privacy Notice and Terms of Use.
Med-IQ
Increasing Diagnostic Acumen for Bipolar I Disorder
E-Publication E-Publication

Increasing Diagnostic Acumen for Bipolar I Disorder


Released:
7/20/18
Expires:
7/19/19

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
7/20/18

Expires:
7/19/19

Maximum Credits:
0.5
E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
7/20/18
Expires:
7/19/19


Maximum Credits:
0.5


Overview: This 30-minute publication discusses the identification of patients with bipolar I disorder, including challenges in making the correct diagnosis, effective communication with patients, and strategies for overcoming patient-related barriers to effective treatment. In addition, it incorporates audio clips of expert faculty discussing key data from two national Med-IQ surveys of psychiatrists, nurse practitioners, and nurses.

CME Information:

Faculty
Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY

Kristen Kichefski, MSN, MBA, RN-BC
Nursing Professional Development Specialist
McLean Hospital
Belmont, MA

Mary Moller, DNP, ARNP, APRN, PMHCNS-BC, CPRP, FAAN
Associate Professor of Nursing
Pacific Lutheran University
Tacoma, WA

Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD

Julie Blum, PhD
Senior Clinical Content Manager
Med-IQ
Baltimore, MD

Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI

Writer
Naseem Bazargan
MedLitera
Vashon, WA

Learning Objectives
Upon completion, participants should be able to:

  • Incorporate available screening tools and clinical criteria to distinguish the symptoms of bipolar I disorder from those of other psychiatric disorders

Target Audience
This activity is intended for psychiatrists, psychiatric nurse practitioners, and psychiatric nurses.
 
Statement of Need
Bipolar I disorder is underrecognized in clinical practice and is frequently misdiagnosed. Such missed opportunities are associated with negative consequences; diagnostic delay predicts poor prognosis in patients with bipolar disorder, and the suicide rate in people with untreated disease is 20 times higher than that of the general population. Once patients are diagnosed, clinicians face several challenges in selecting optimal treatment to meet patients’ disease-management needs and goals. For instance, there are several pharmacologic agents with different routes of administration that clinicians can consider for their patients. Thus, providers need to understand how to craft individualized, patient-centered treatment plans to ensure optimal adherence and disease-related outcomes and reduce the burden of bipolar disease on patients, their caregivers, and healthcare systems.
 
Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Med-IQ is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This nursing activity has been approved for up to 0.5 contact hour.

Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME/CE activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME/CE material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: July 20, 2018
Expiration Date: July 19, 2019
Estimated Time to Complete This Activity: 30 minutes
 
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Leslie Citrome, MD, MPH
Consulting fees/advisory boards: ACADIA Pharmaceuticals Inc., Alkermes, Allergan, Inc., Intra-Cellular Therapies, Inc., Janssen Pharmaceuticals, Inc., Lundbeck, Merck & Co., Inc., Neurocrine Biosciences, Noven Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Shire, Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals North America, Inc., Teva Neuroscience, Inc., Vanda Pharmaceuticals, Inc.
Fees received for promotional/non-CME activities: ACADIA Pharmaceuticals Inc., Alkermes, Allergan, Inc., Janssen Pharmaceuticals, Inc., Lundbeck, Merck & Co., Inc., Neurocrine Biosciences, Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Shire, Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals North America, Inc., Teva Neuroscience, Inc., Vanda Pharmaceuticals, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc.

Kristen Kichefski, MSN, MBA, RN-BC
Other (spouse): Alnylam Pharmaceuticals, Inc.

Mary Moller, DNP, ARNP, APRN, PMHCNS-BC, CPRP, FAAN
Fees received for promotional/non-CME activities: Alkermes

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information 
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Browser
Microsoft Internet Explorer 8.0 or later

Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/
 
Google Chrome - latest version
Download: http://www.google.com/chrome
 
Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/ 
 
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support
 
ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.  

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Copyright
© 2018 Med-IQ, Inc.

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.